Advisors Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $141K | Sell |
1,878
-957
| -34% | -$75.5K | ﹤0.01% | 1206 |
|
|
2025
Q4 | $224K | Sell |
2,835
-2,619
| -48% | -$197K | ﹤0.01% | 1112 |
|
|
2025
Q3 | $357K | Sell |
5,454
-545
| -9% | -$26.6K | 0.01% | 1027 |
|
|
2025
Q2 | $237K | Sell |
5,999
-49
| -0.8% | -$1.6K | ﹤0.01% | 1089 |
|
|
2025
Q1 | $182K | Sell |
6,048
-22
| -0.4% | -$720 | ﹤0.01% | 1122 |
|
|
2024
Q4 | $212K | Sell |
6,070
-70
| -1% | -$2.62K | ﹤0.01% | 1109 |
|
|
2024
Q3 | $246K | Buy |
6,140
+1,066
| +21% | +$49.6K | ﹤0.01% | 1070 |
|
|
2024
Q2 | $242K | Buy |
5,074
+1,896
| +60% | +$77.8K | ﹤0.01% | 1062 |
|
|
2024
Q1 | $138K | Buy |
3,178
+2,875
| +949% | +$137K | ﹤0.01% | 1187 |
|
|
2023
Q4 | $15.3K | Buy |
+303
| New | +$14.5K | ﹤0.01% | 1369 |
|
|
2021
Q4 | – | Sell |
-3,164
| Closed | -$106K | – | 1503 |
|
|
2021
Q3 | $106K | Sell |
3,164
-15
| -0.5% | -$565 | ﹤0.01% | 1300 |
|
|
2021
Q2 | $127K | Sell |
3,179
-29
| -0.9% | -$1.14K | ﹤0.01% | 1277 |
|
|
2021
Q1 | $144K | Sell |
3,208
-6,792
| -68% | -$379K | ﹤0.01% | 1274 |
|
|
2020
Q4 | $565K | Sell |
10,000
-6,683
| -40% | -$333K | 0.01% | 929 |
|
|
2020
Q3 | $792K | Sell |
16,683
-904
| -5% | -$50.2K | 0.01% | 771 |
|
|
2020
Q2 | $1.04M | Sell |
17,587
-246
| -1% | -$13.7K | 0.02% | 681 |
|
|
2020
Q1 | $843K | Buy |
17,833
+1,371
| +8% | +$76.4K | 0.02% | 667 |
|
|
2019
Q4 | $994K | Sell |
16,462
-2,539
| -13% | -$151K | 0.02% | 764 |
|
|
2019
Q3 | $1.14M | Sell |
19,001
-5,945
| -24% | -$387K | 0.02% | 707 |
|
|
2019
Q2 | $1.6M | Sell |
24,946
-3,647
| -13% | -$258K | 0.03% | 630 |
|
|
2019
Q1 | $2.32M | Buy |
28,593
+7,338
| +35% | +$473K | 0.04% | 491 |
|
|
2018
Q4 | $1.15M | Buy |
21,255
+2,482
| +13% | +$127K | 0.02% | 707 |
|
|
2018
Q3 | $968K | Sell |
18,773
-681
| -4% | -$32K | 0.02% | 846 |
|
|
2018
Q2 | $811K | Sell |
19,454
-7,634
| -28% | -$338K | 0.01% | 912 |
|
|
2018
Q1 | $1.43M | Buy |
27,088
+739
| +3% | +$37.5K | 0.02% | 705 |
|
|
2017
Q4 | $1.32M | Buy |
26,349
+8,697
| +49% | +$477K | 0.02% | 742 |
|
|
2017
Q3 | $895K | Buy |
17,652
+9,094
| +106% | +$476K | 0.02% | 900 |
|
|
2017
Q2 | $435K | Buy |
8,558
+2,016
| +31% | +$93.9K | 0.01% | 1129 |
|
|
2017
Q1 | $263K | Buy |
6,542
+4,262
| +187% | +$191K | ﹤0.01% | 1253 |
|
|
2016
Q4 | $109K | Sell |
2,280
-1,911
| -46% | -$75.6K | ﹤0.01% | 1502 |
|
|
2016
Q3 | $154K | Sell |
4,191
-1,872
| -31% | -$58.6K | ﹤0.01% | 1411 |
|
|
2016
Q2 | $141K | Sell |
6,063
-545
| -8% | -$17.6K | ﹤0.01% | 1429 |
|
|
2016
Q1 | $268K | Sell |
6,608
-115
| -2% | -$4.67K | ﹤0.01% | 1251 |
|
|
2015
Q4 | $416K | Sell |
6,723
-7,529
| -53% | -$406K | 0.01% | 1204 |
|
|
2015
Q3 | $576K | Buy |
14,252
+2,409
| +20% | +$125K | 0.01% | 1035 |
|
|
2015
Q2 | $682K | Buy |
11,843
+5,149
| +77% | +$327K | 0.01% | 1021 |
|
|
2015
Q1 | $426K | Buy |
6,694
+4,049
| +153% | +$275K | 0.01% | 1151 |
|
|
2014
Q4 | $163K | Sell |
2,645
-109
| -4% | -$5.38K | ﹤0.01% | 1359 |
|
|
2014
Q3 | $107K | Buy |
2,754
+53
| +2% | +$1.88K | ﹤0.01% | 1426 |
|
|
2014
Q2 | $93K | Buy |
2,701
+1,936
| +253% | +$61K | ﹤0.01% | 1482 |
|
|
2014
Q1 | $33K | Buy |
+765
| New | +$37.1K | ﹤0.01% | 1699 |
|
Other funds holding IONS
VPM
VCM
Advisors Asset Management's IONS Position: Q1 2026 in Review
Advisors Asset Management reduced its Ionis Pharmaceuticals (IONS) stake by 34% in Q1 2026, selling an estimated $75.5K and leaving 1,878 shares worth $141K. The position accounts for ﹤0.01% of the portfolio, ranked #1206.
Advisors Asset Management first reported a position in IONS in Q1 2014 and has held it in 41 quarters since. The position peaked at $2.32M in Q1 2019. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.
- Advisors Asset Management held 1,878 shares of Ionis Pharmaceuticals worth $141K as of Q1 2026.
- Advisors Asset Management sold 957 Ionis Pharmaceuticals shares in Q1 2026, an estimated $75.5K.
- Ionis Pharmaceuticals made up ﹤0.01% of Advisors Asset Management's portfolio in Q1 2026, its #1206 holding.
- Advisors Asset Management first reported a position in Ionis Pharmaceuticals in Q1 2014 and has held it in 41 quarters since.
- Advisors Asset Management's Ionis Pharmaceuticals position peaked at $2.32M in Q1 2019.
- 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.
Based on Advisors Asset Management's 13F filing for Q1 2026, filed 15 May 2026.